We evaluated rates and determinants of virological failure in triple-class experienced patients receiving raltegravirbased regimens from a national observational study over 48 weeks, defined by any one of the following: (1) no HIV-RNA suppression to undetectable levels (>50 copies/mL) during follow-up; (2) detectable viral load after obtaining undetectable levels; and (3) leaving the study before 48 weeks. Among 101 eligible patients, 26 (25.7%; 95% CI 17.2-34.2) had virological failure. No significant differences between patients with and without virological failure were observed for gender, age, route of transmission, baseline CD4/ HIV-RNA, CDC group, hepatitis B or C co-infections, resistance (based on the last genotype available), type and number of concomitant drug classes, concomitant use of darunavir, atazanavir, etravirine, enfuvirtide or maraviroc, and health-related qualityof- life measures. A high rate of treatment response was observed. The analyses did not identify any baseline factor associated with failure, including resistance status. Even if we cannot exclude the presence of pre-existing minority resistant variants not captured by genotypic tests, the lack of baseline predictors of failure suggests the need to monitor patients closely during follow up for other factors, such as potential drug interactions and reduced levels of adherence, which may favour virological failure.

Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors / R., Bucciardini; D'Ettorre, Gabriella; S., Baroncelli; Ceccarelli, Giancarlo; G., Parruti; L. E., Weimer; V., Fragola; C. M., Galluzzo; M. F., Pirillo; S., Lucattini; R., Bellagamba; D., Francisci; N., Ladisa; A. D., Antoni; A., Degli Antoni; G., Guaraldi; P. E., Manconi; Vullo, Vincenzo; R., Preziosi; O., Cirioni; G., Verucchi; M., Iss Nia Study Group Floridia; F. O. R., The Iss Nia Study Group. - In: INTERNATIONAL JOURNAL OF STD & AIDS. - ISSN 0956-4624. - ELETTRONICO. - 23:7(2012), pp. 459-463. [10.1258/ijsa.2012.011391]

Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors

D'ETTORRE, Gabriella;CECCARELLI, GIANCARLO;VULLO, Vincenzo;
2012

Abstract

We evaluated rates and determinants of virological failure in triple-class experienced patients receiving raltegravirbased regimens from a national observational study over 48 weeks, defined by any one of the following: (1) no HIV-RNA suppression to undetectable levels (>50 copies/mL) during follow-up; (2) detectable viral load after obtaining undetectable levels; and (3) leaving the study before 48 weeks. Among 101 eligible patients, 26 (25.7%; 95% CI 17.2-34.2) had virological failure. No significant differences between patients with and without virological failure were observed for gender, age, route of transmission, baseline CD4/ HIV-RNA, CDC group, hepatitis B or C co-infections, resistance (based on the last genotype available), type and number of concomitant drug classes, concomitant use of darunavir, atazanavir, etravirine, enfuvirtide or maraviroc, and health-related qualityof- life measures. A high rate of treatment response was observed. The analyses did not identify any baseline factor associated with failure, including resistance status. Even if we cannot exclude the presence of pre-existing minority resistant variants not captured by genotypic tests, the lack of baseline predictors of failure suggests the need to monitor patients closely during follow up for other factors, such as potential drug interactions and reduced levels of adherence, which may favour virological failure.
2012
hiv; antiretroviral therapy; salvage regimen; virological failure; raltegravir
01 Pubblicazione su rivista::01a Articolo in rivista
Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors / R., Bucciardini; D'Ettorre, Gabriella; S., Baroncelli; Ceccarelli, Giancarlo; G., Parruti; L. E., Weimer; V., Fragola; C. M., Galluzzo; M. F., Pirillo; S., Lucattini; R., Bellagamba; D., Francisci; N., Ladisa; A. D., Antoni; A., Degli Antoni; G., Guaraldi; P. E., Manconi; Vullo, Vincenzo; R., Preziosi; O., Cirioni; G., Verucchi; M., Iss Nia Study Group Floridia; F. O. R., The Iss Nia Study Group. - In: INTERNATIONAL JOURNAL OF STD & AIDS. - ISSN 0956-4624. - ELETTRONICO. - 23:7(2012), pp. 459-463. [10.1258/ijsa.2012.011391]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/610240
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 10
social impact